BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema
November 07, 2013 at 11:53 AM EST
BioCryst Pharmaceuticals (NASDAQ: BCRX ) today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered